As the tools for reading and editing biology improve, we aim to understand which discoveries can become treatments, tests, and products that reach patients and hold up commercially.
Most discoveries never leave the lab, and the ones that do take years to prove. Between a promising result and a product a doctor can use lie trials, manufacturing, and approvals, each with its own risks. We look for teams who treat every one of those steps as part of the science.
We carry programs through the hardest middle miles, with capabilities spanning trial design, regulatory strategy, and the clinical operations that separate promising data from approved products.
Our companies build the technologies that detect disease earlier and guide treatment decisions, from point-of-care testing to advanced molecular platforms deployed in health systems worldwide.
Through our subsidiaries, we operate across the earliest stages of science, including the laboratories, instruments, data platforms, and research services that turn hypotheses into validated discoveries.
We design for volume from day one, with process development, manufacturing capacity, and supply chain infrastructure that carry a therapy from first batch to patients everywhere.
We own, acquire, invest in, and build businesses, and each deal starts with the role the company needs. As your business changes, our role changes with it.
Sign up for our latest insights and firm announcements.
We respect your privacy and will not share your information.
